MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. The projects aim to develop novel therapeutics for the treatment of cystic fibrosis and of respiratory syncytial virus, respectively. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/two-new-lab150-projects-identified-to-create-novel-therapeutics-for-cystic-fibrosis-and-respiratory-syncytial-virus-5781
